Recursion Pharmaceuticals Inc (RXRX NASDAQ) stock market data APIs
$4.1225
0.01(0.2%)
as of December 31, 2025
Try our APIs with
free plan!
Recursion Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Prev. Close
4.1225
Open
4.1286
High
4.1286
Low
4.0151
52 wk Range
3.79-12.36
Market Cap
2 132 M
Shares Outstanding
514 M
Revenue
43 689 K
EPS
-0.36
Beta
0.937
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Recursion Pharmaceuticals Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Recursion Pharmaceuticals Inc data using free add-ons & libraries
Get Recursion Pharmaceuticals Inc Fundamental Data
Recursion Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 43 689 K
- EBITDA: -637 875 968
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-05
- EPS/Forecast: -0.37
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Recursion Pharmaceuticals Inc News
New
Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy.
Key Points Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its ...
Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy.
Key Points Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its ...
Cathie Wood’s ARK Investment Buys 755K Shares Of Recursion Pharmaceuticals, Inc. (RXRX)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the 12 Best Genomics Stocks to Invest In.Cathie Wood’s ARK Investment Buys 755K Shares Of Recursion Pharmaceuticals, Inc. (RXRX) Cathie Wood�...
Recursion Pharmaceuticals Reports Positive Phase 1b/2 TUPELO Trial Results, Validating AI-Driven Therapy for FAP
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the AI stocks under $20 to buy now. On December 8, Recursion Pharmaceuticals announced positive Phase 1b/2 results from its ongoing TUPELO trial ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
